GSA Capital Partners’s Arcturus Therapeutics ARCT Stock Holding History

GSA Capital Partners’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330K	Sell	49,145 -84,565	-63%	-$667K	0.02%	1246
2026 Q1	$1.03M	Buy	+133,710	New	+$976K	0.06%	481
2025 Q4	–	Sell	-49,012	Closed	-$903K	–	1660
2025 Q3	$903K	Buy	49,012 +9,459	+24%	+$152K	0.08%	459
2025 Q2	$515K	Buy	+39,553	New	+$468K	0.04%	903
2025 Q1	–	Sell	-29,476	Closed	-$500K	–	1632
2024 Q4	$500K	Buy	29,476 +20,059	+213%	+$378K	0.04%	886
2024 Q3	$219K	Sell	9,417 -52,213	-85%	-$1.12M	0.02%	1381
2024 Q2	$1.5M	Buy	+61,630	New	+$1.87M	0.1%	275
2023 Q2	–	Sell	-28,827	Closed	-$691K	–	1498
2023 Q1	$691K	Buy	28,827 +18,546	+180%	+$333K	0.07%	513
2022 Q4	$174K	Buy	+10,281	New	+$179K	0.02%	1214
2022 Q3	–	Sell	-51,848	Closed	-$816K	–	1494
2022 Q2	$816K	Buy	+51,848	New	+$1.02M	0.12%	220
2021 Q2	–	Sell	-5,311	Closed	-$219K	–	1304
2021 Q1	$219K	Sell	5,311 -1,200	-18%	-$71.5K	0.04%	844
2020 Q4	$282K	Buy	+6,511	New	+$441K	0.05%	774

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GSA Capital Partners's ARCT Position: Q2 2026 in Review

GSA Capital Partners reduced its Arcturus Therapeutics (ARCT) stake by 63% in Q2 2026, selling an estimated $667K and leaving 49,145 shares worth $330K. The position accounts for 0.02% of the portfolio, ranked #1246.

GSA Capital Partners first reported a position in ARCT in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.5M in Q2 2024. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

GSA Capital Partners held 49,145 shares of Arcturus Therapeutics worth $330K as of Q2 2026.
GSA Capital Partners sold 84,565 Arcturus Therapeutics shares in Q2 2026, an estimated $667K.
Arcturus Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1246 holding.
GSA Capital Partners first reported a position in Arcturus Therapeutics in Q4 2020 and has held it in 12 quarters since.
GSA Capital Partners's Arcturus Therapeutics position peaked at $1.5M in Q2 2024.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.